Developer docs
API playgroundTry for free, no card

Search company profiles

Avant Technologies

Full company profile

uuid0002gmh

Namestring
Avant Technologies
Legal namestring
Avant Technologies Inc.
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Avant Technologies is a healthcare technology company operating two parallel platforms: an AI-driven diagnostics platform branded VisionAI and a portfolio of cell-based therapies built around the licensed Cell-in-a-Box® microencapsulation technology. VisionAI applies computer vision and predictive analytics to retinal camera imagery to detect multiple conditions — diabetic retinopathy, cardiovascular disease, chronic kidney disease, liver fibrosis, type 2 diabetes, lung abnormalities, and early-stage dementia — with algorithms validated against over 2.3 million data points through a strategic collaboration with Apollo Hospitals in India. The cell-therapy pipeline targets type 1 and insulin-dependent type 2 diabetes through the Insulinova joint venture with SGAustria (reporting an 83% insulin independence rate in recent clinical trials) and age-related diseases through the Klothonova joint venture with Austrianova using α-Klotho protein overexpression. The company's revenue model is licensing- and royalty-based, executed through joint venture entities rather than direct sales: Ai-nova Acquisition Corp. (with Ainnova Tech) holds global commercialization rights for VisionAI, while Insulinova and Klothonova hold development and commercialization rights for their respective therapies; additional revenue capability comes from AI-driven healthcare data interoperability services inherited via the April 2024 acquisition of Wired-4-Health. No public pricing is disclosed. The company is pre-commercial or early-commercial: active clinical deployments exist in Chile, Dominican Republic, and Mexico, planned entry into Brazil is contingent on ANVISA approval, and U.S. market entry for VisionAI is contingent on FDA 510(k) clearance (pre-submission meeting completed May 2025). In April 2026, Tech Mahindra announced acquisition of an 85% stake in the Canada-incorporated Avant Technologies entity for CAD 28 million (with the remaining 15% to follow), a transaction primarily motivated by Tech Mahindra's BFSI ambitions rather than the healthcare pipeline itself. Note: the financial metrics block in the input data (revenue in the hundreds of billions, EV in the tens of trillions) is internally inconsistent with the firmographic profile (1-10 employees, private, founded 2019, CAD 28 million acquisition price) and is not used in this analysis.

Short descriptiontext

Avant Technologies is a healthcare technology company developing AI-driven retinal diagnostics (VisionAI) for early multi-disease detection and proprietary cell-based therapies for diabetes and age-related diseases through joint ventures with Ainnova Tech, SGAustria, and Austrianova.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLas Vegas, United States
HQ citystring
Las Vegas
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
AI medical diagnostics, cell encapsulation therapy, diabetic retinopathy screening, regenerative medicine therapeutics, healthcare data interoperability
Industry6 codes
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAHAHAJ
Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHAJAB
Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLAFAKAI
Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging)
NAICS code4 codes
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
  • Ophthalmic Goods Manufacturing339115
  • Offices of Optometrists62132
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Ophthalmic Goods3851
Product category
AI Medical Diagnostics Software
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1AI Diagnostics Platform Licensing
TypeLicensing Royalties
Description

Commercialization of the VisionAI platform for early disease detection through licensing and commercialization rights held by Ai-nova Acquisition Corp., targeting healthcare providers, opticians, and eye care centers in North America, Europe, and Latin America.

globenewswire.com
2Cell-Based Therapy Development and Commercialization
TypeLicensing Royalties
Description

Development of cell encapsulation therapies for diabetes and age-related diseases through joint ventures (Insulinova for diabetes, Klothonova for α-Klotho), targeting global markets for type 1 and insulin-dependent type 2 diabetes treatments and anti-aging therapies.

businesswire.com
3Healthcare Data Interoperability Services
TypeProfessional Services
Description

AI-driven data interoperability and computational capabilities in healthcare supporting improved outcomes and cost efficiencies, gained through the acquisition of Wired-4-Health.

ih.advfn.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Avant Technologies commercializes the VisionAI AI-driven diagnostic platform for early detection of multiple diseases via retinal image analysis, and develops proprietary cell-based therapies using Cell-in-a-Box® encapsulation technology for diabetes and age-related conditions. Offerings are delivered through joint ventures (Ai-nova Acquisition Corp., Insulinova, Klothonova) and targeted at healthcare providers, hospitals, opticians, and eye-care centers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 83% insulin independence rate in recent clinical trials for diabetes cell therapies
+2 more records
Product and service1 record
1VisionAI Platform
CategoryAI Medical Diagnostics Software
Description

AI-driven diagnostic platform that analyzes retinal camera images using computer vision and predictive analytics to detect multiple diseases early, including diabetic retinopathy, cardiovascular disease, chronic kidney disease, liver fibrosis, type 2 diabetes, and lung abnormalities. Algorithms are validated with over 2.3 million data points and the platform is under FDA 510(k) review for diabetic retinopathy screening. Sold to healthcare providers, opticians, and eye care centers.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-04
Description

Joint venture Insulinova, Inc. formed between Avant Technologies and SGAustria to develop a stem cell-based diabetes treatment. The partnership combines SGAustria's Cell-in-a-Box® cell encapsulation technology with Avant's funding and development efforts to create scalable solutions for type 1 and insulin-dependent type 2 diabetes globally.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-22
Description

Joint venture Klothonova LLC launched by Avant Technologies and Austrianova to develop cellular therapies using the 'Longevity Protein' Klotho to combat age-related diseases. The program has demonstrated proof of concept with encapsulated cells overproducing Klotho and is moving toward preclinical and clinical studies using Austrianova's cell-encapsulation technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-10
Description

Strategic collaboration with Apollo Hospitals to deploy AI algorithms for early detection of cardiovascular disease, chronic kidney disease, liver fibrosis, type 2 diabetes, and lung abnormalities. Avant holds an exclusive license for AI algorithms validated with over 2.3 million data points, with commercial pilot programs launching across the Americas and planned expansion to Brazil.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-12
Description

Avant Technologies and Ainnova Tech formed a joint venture through Ai-nova Acquisition Corp to commercialize Ainnova's VisionAI platform and retinal camera technology for early disease detection across North America and Europe. Avant's capital investment scales AI-powered diagnostic solutions including diabetic retinopathy screening and cardiovascular risk assessment.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-04-09
Description

Avant Technologies completed its acquisition of Wired-4-Health, a healthcare technology and data integration services firm, on April 9, 2024. The merger aims to enhance AI-driven data interoperability and computational capabilities in healthcare, supporting improved outcomes and cost efficiencies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI platform for eye disease screening including diabetic retinopathy (EyeArt), FDA-cleared. Directly competes in the same AI retinal screening category and primary care/eye care deployment model.

2Sigilon Therapeutics
TypeEmerging player
Description

Encapsulated cell therapies for type 1 diabetes and rare diseases using Afibromer technology. Comparable in the encapsulated live-cell therapy category targeting diabetes.

TypeDirect peer
Description

FDA-cleared autonomous AI for diabetic retinopathy screening (IDx-DR). Closest US-market comparable to Avant's VisionAI diabetic retinopathy indication, competing for the same ophthalmology and primary care screening channels.

TypeDirect peer
Description

AI-based retinal screening for diabetic retinopathy with FDA clearance. Direct peer in the autonomous AI diagnostic category targeting similar primary care and optometry deployment.

5Tempus AI
TypeBroad incumbent
Description

AI-driven precision medicine platform with broad diagnostics, multi-omics, and clinical decision support offerings. Comparable as a broader healthcare AI/diagnostics incumbent pursuing multi-condition clinical AI.

TypeDirect peer
Description

Cell therapy company developing Cell Pouch system for insulin-dependent diabetes. Closest peer to Avant's Insulinova program in encapsulated cell-based diabetes treatment.

TypeBroad incumbent
Description

Major tech incumbent developing AI for medical imaging and diagnostics including retinal screening. Competes at the platform level for healthcare AI talent, datasets, and clinical partnerships.

TypeOthers
Description

Cell encapsulation technology provider and Avant's JV partner for Klothonova. Adjacent enabler rather than competitor; provides the underlying Cell-in-a-Box encapsulation platform Avant licenses for therapeutic programs.

TypeDirect peer
Description

AI-driven retinal imaging diagnostics company; Avant's joint venture partner for VisionAI commercialization. Directly comparable as the originator of the core AI screening technology Avant distributes.

10ViaCyte (now part of Vertex)
TypeDirect peer
Description

Stem cell-derived islet cell therapy for type 1 diabetes, recently acquired by Vertex. Directly comparable to Insulinova's stem cell-based diabetes approach with similar clinical-stage asset.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses2 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Avant Technologies

AI Medical Diagnostics Softwareavanttechnologies.com

Avant Technologies is a healthcare technology company developing AI-driven retinal diagnostics (VisionAI) for early multi-disease detection and proprietary cell-based therapies for diabetes and age-related diseases through joint ventures with Ainnova Tech, SGAustria, and Austrianova.

What Avant Technologies does

Avant Technologies is a healthcare technology company operating two parallel platforms: an AI-driven diagnostics platform branded VisionAI and a portfolio of cell-based therapies built around the licensed Cell-in-a-Box® microencapsulation technology. VisionAI applies computer vision and predictive analytics to retinal camera imagery to detect multiple conditions — diabetic retinopathy, cardiovascular disease, chronic kidney disease, liver fibrosis, type 2 diabetes, lung abnormalities, and early-stage dementia — with algorithms validated against over 2.3 million data points through a strategic collaboration with Apollo Hospitals in India. The cell-therapy pipeline targets type 1 and insulin-dependent type 2 diabetes through the Insulinova joint venture with SGAustria (reporting an 83% insulin independence rate in recent clinical trials) and age-related diseases through the Klothonova joint venture with Austrianova using α-Klotho protein overexpression. The company's revenue model is licensing- and royalty-based, executed through joint venture entities rather than direct sales: Ai-nova Acquisition Corp. (with Ainnova Tech) holds global commercialization rights for VisionAI, while Insulinova and Klothonova hold development and commercialization rights for their respective therapies; additional revenue capability comes from AI-driven healthcare data interoperability services inherited via the April 2024 acquisition of Wired-4-Health. No public pricing is disclosed. The company is pre-commercial or early-commercial: active clinical deployments exist in Chile, Dominican Republic, and Mexico, planned entry into Brazil is contingent on ANVISA approval, and U.S. market entry for VisionAI is contingent on FDA 510(k) clearance (pre-submission meeting completed May 2025). In April 2026, Tech Mahindra announced acquisition of an 85% stake in the Canada-incorporated Avant Technologies entity for CAD 28 million (with the remaining 15% to follow), a transaction primarily motivated by Tech Mahindra's BFSI ambitions rather than the healthcare pipeline itself. Note: the financial metrics block in the input data (revenue in the hundreds of billions, EV in the tens of trillions) is internally inconsistent with the firmographic profile (1-10 employees, private, founded 2019, CAD 28 million acquisition price) and is not used in this analysis.

Avant Technologies firmographics

Firmographics
Name
Avant Technologies
Legal name
Avant Technologies Inc.
Website
https://avanttechnologies.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Avant Technologies is a healthcare technology company developing AI-driven retinal diagnostics (VisionAI) for early multi-disease detection and proprietary cell-based therapies for diabetes and age-related diseases through joint ventures with Ainnova Tech, SGAustria, and Austrianova.
Ownership category
akta.pro rank

Avant Technologies industry classification

Industry
Product category
AI Medical Diagnostics Software
NAICS
Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Ophthalmic Goods Manufacturing (339115), Offices of Optometrists (62132), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851)
akta.pro industry
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAHAHAJ
Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHAJAB
Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLAFAKAI
Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging)

Keywords

  • AI medical diagnostics
  • Cell encapsulation therapy
  • Diabetic retinopathy screening
  • Regenerative medicine therapeutics
  • Healthcare data interoperability

Where Avant Technologies is headquartered

Location

Headquarters

HQ city
Las Vegas
HQ country
United States
HQ region
North America

Markets served

Avant Technologies business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. AI Diagnostics Platform Licensing: Commercialization of the VisionAI platform for early disease detection through licensing and commercialization rights held by Ai-nova Acquisition Corp., targeting healthcare providers, opticians, and eye care centers in North America, Europe, and Latin America.
  2. Cell-Based Therapy Development and Commercialization: Development of cell encapsulation therapies for diabetes and age-related diseases through joint ventures (Insulinova for diabetes, Klothonova for α-Klotho), targeting global markets for type 1 and insulin-dependent type 2 diabetes treatments and anti-aging therapies.
  3. Healthcare Data Interoperability Services: AI-driven data interoperability and computational capabilities in healthcare supporting improved outcomes and cost efficiencies, gained through the acquisition of Wired-4-Health.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels4 records

Avant Technologies product offering

Product offering

Core offering

Avant Technologies commercializes the VisionAI AI-driven diagnostic platform for early detection of multiple diseases via retinal image analysis, and develops proprietary cell-based therapies using Cell-in-a-Box® encapsulation technology for diabetes and age-related conditions. Offerings are delivered through joint ventures (Ai-nova Acquisition Corp., Insulinova, Klothonova) and targeted at healthcare providers, hospitals, opticians, and eye-care centers.

Differentiator

Problem solved

Functional benefit

Products and services

  • VisionAI Platform AI-driven diagnostic platform that analyzes retinal camera images using computer vision and predictive analytics to detect multiple diseases early, including diabetic retinopathy, cardiovascular disease, chronic kidney disease, liver fibrosis, type 2 diabetes, and lung abnormalities. Algorithms are validated with over 2.3 million data points and the platform is under FDA 510(k) review for diabetic retinopathy screening. Sold to healthcare providers, opticians, and eye care centers.

Quantifiable outcome

  • 83% insulin independence rate in recent clinical trials for diabetes cell therapies
  • +2 more outcomes

Companies that use Avant Technologies

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Avant Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Avant Technologies partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • SGAustria Pte. Ltd.coreStrategic or Co-development Partner · 4 November 2025Joint venture Insulinova, Inc. formed between Avant Technologies and SGAustria to develop a stem cell-based diabetes treatment. The partnership combines SGAustria's Cell-in-a-Box® cell encapsulation technology with Avant's funding and development efforts to create scalable solutions for type 1 and insulin-dependent type 2 diabetes globally.
  • AustrianovacoreStrategic or Co-development Partner · 22 October 2025Joint venture Klothonova LLC launched by Avant Technologies and Austrianova to develop cellular therapies using the 'Longevity Protein' Klotho to combat age-related diseases. The program has demonstrated proof of concept with encapsulated cells overproducing Klotho and is moving toward preclinical and clinical studies using Austrianova's cell-encapsulation technology.
  • Apollo HospitalscoreStrategic or Co-development Partner · 10 March 2025Strategic collaboration with Apollo Hospitals to deploy AI algorithms for early detection of cardiovascular disease, chronic kidney disease, liver fibrosis, type 2 diabetes, and lung abnormalities. Avant holds an exclusive license for AI algorithms validated with over 2.3 million data points, with commercial pilot programs launching across the Americas and planned expansion to Brazil.
  • Ainnova Tech, Inc.coreStrategic or Co-development Partner · 12 November 2024Avant Technologies and Ainnova Tech formed a joint venture through Ai-nova Acquisition Corp to commercialize Ainnova's VisionAI platform and retinal camera technology for early disease detection across North America and Europe. Avant's capital investment scales AI-powered diagnostic solutions including diabetic retinopathy screening and cardiovascular risk assessment.
  • Wired-4-HealthcoreTechnology or Integration · 9 April 2024Avant Technologies completed its acquisition of Wired-4-Health, a healthcare technology and data integration services firm, on April 9, 2024. The merger aims to enhance AI-driven data interoperability and computational capabilities in healthcare, supporting improved outcomes and cost efficiencies.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Avant Technologies competitors and assessment

Company assessment

Direct peers

  • Eyenuk: AI platform for eye disease screening including diabetic retinopathy (EyeArt), FDA-cleared. Directly competes in the same AI retinal screening category and primary care/eye care deployment model.
  • Digital Diagnostics: FDA-cleared autonomous AI for diabetic retinopathy screening (IDx-DR). Closest US-market comparable to Avant's VisionAI diabetic retinopathy indication, competing for the same ophthalmology and primary care screening channels.
  • AEYE Health: AI-based retinal screening for diabetic retinopathy with FDA clearance. Direct peer in the autonomous AI diagnostic category targeting similar primary care and optometry deployment.
  • Sernova Corp: Cell therapy company developing Cell Pouch system for insulin-dependent diabetes. Closest peer to Avant's Insulinova program in encapsulated cell-based diabetes treatment.
  • Ainnova Tech: AI-driven retinal imaging diagnostics company; Avant's joint venture partner for VisionAI commercialization. Directly comparable as the originator of the core AI screening technology Avant distributes.
  • ViaCyte (now part of Vertex): Stem cell-derived islet cell therapy for type 1 diabetes, recently acquired by Vertex. Directly comparable to Insulinova's stem cell-based diabetes approach with similar clinical-stage asset.

Emerging players

  • Sigilon Therapeutics: Encapsulated cell therapies for type 1 diabetes and rare diseases using Afibromer technology. Comparable in the encapsulated live-cell therapy category targeting diabetes.

Broad incumbents

  • Tempus AI: AI-driven precision medicine platform with broad diagnostics, multi-omics, and clinical decision support offerings. Comparable as a broader healthcare AI/diagnostics incumbent pursuing multi-condition clinical AI.
  • Google Health (Verily/Google DeepMind): Major tech incumbent developing AI for medical imaging and diagnostics including retinal screening. Competes at the platform level for healthcare AI talent, datasets, and clinical partnerships.

Others

  • Austrianova: Cell encapsulation technology provider and Avant's JV partner for Klothonova. Adjacent enabler rather than competitor; provides the underlying Cell-in-a-Box encapsulation platform Avant licenses for therapeutic programs.

Market position

Strengths5 records

Weaknesses2 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Avant Technologies social profiles

Digital presence

Avant Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Avant Technologies leadership team

Management profile

Number of profiles

Profiles1 record

Avant Technologies subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Avant Technologies funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Avant Technologies M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avant Technologies

What does Avant Technologies do?

Avant Technologies commercializes the VisionAI AI-driven diagnostic platform for early detection of multiple diseases via retinal image analysis, and develops proprietary cell-based therapies using Cell-in-a-Box® encapsulation technology for diabetes and age-related conditions. Offerings are delivered through joint ventures (Ai-nova Acquisition Corp., Insulinova, Klothonova) and targeted at healthcare providers, hospitals, opticians, and eye-care centers.

Is Avant Technologies a public or private company?

Avant Technologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was Avant Technologies founded?

Avant Technologies was founded in 2019. It employs 1 to 10 people.

Where is Avant Technologies based?

Avant Technologies is headquartered in Las Vegas, United States, in the North America region.

How does Avant Technologies make money?

Three revenue lines are on record. AI Diagnostics Platform Licensing is the primary driver. The others are cell-Based Therapy Development and Commercialization and healthcare Data Interoperability Services.

Who are Avant Technologies's main competitors?

Direct peers on record are Eyenuk, Digital Diagnostics, AEYE Health, Sernova Corp, Ainnova Tech and ViaCyte (now part of Vertex). Sigilon Therapeutics is listed as an emerging player. Broad incumbents are Tempus AI and Google Health (Verily/Google DeepMind). Austrianova is listed as an others.

Does Avant Technologies have an API?

No public API is recorded for Avant Technologies.

What industry is Avant Technologies in?

Avant Technologies's product category is AI Medical Diagnostics Software. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLAHAHAJ, Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators). Its NAICS code is 3345 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
WhalesbookTech Mahindra Acquires Avant Technologies to Expand BFSI ServicesTech Mahindra is acquiring an initial 85% stake in Canada-based Avant Technologies for CAD 28 million (approximately ₹171 crore), with the remaining 15% to be acquired later through a phased approach. The acquisition aims to strengthen Tech Mahindra's capabilities in the Banking, Financial Services, and Insurance (BFSI) sector, targeting the global IT BFSI market projected to grow from $350 billion in 2023 to $780 billion by 2032. Analysts have responded positively, with most recommending 'Moderate Buy' to 'Buy', reflecting expectations that the deal will accelerate Tech Mahindra's service delivery in key markets including North America.PR NewswireAvant Technologies Evaluating Advanced Cells for Diabetes Therapy at 15th Annual EPITA SymposiumAvant Technologies announced its participation in the 15th EPITA Symposium held January 25-27, 2026, in Igls, Austria, where the company is actively evaluating advanced cells for potential application in diabetes therapy. Dr. Eva Maria Lilli Brandtner is assessing promising cells for use with Avant's Cell-in-a-Box® microencapsulation technology, developed in partnership with Singapore-based SGAustria, which offers immunosuppression-free protection for transplanted insulin-producing cells. The company aims to position itself as a contributor to beta cell replacement therapies for type 1 and insulin-dependent type 2 diabetes patients worldwide.NewswireGene Therapy: 5 Biotech Stocks Chasing the $36B PrizeThe gene therapy market is projected to reach $36.55 billion by 2032, with the cell and gene therapy sector expected to hit $39.61 billion by 2034 at a 17.98% compound annual growth rate. Multiple biotech companies presented positive clinical data: Vertex Pharmaceuticals reported that all patients in its CASGEVY Phase 3 trials for children ages 5-11 with sickle cell disease and beta thalassemia achieved freedom from vaso-occlusive crises and transfusion independence for at least 12 months; CRISPR Therapeutics announced dose-dependent, durable reductions of 73% in ANGPTL3 and significant lipid reductions with its CTX310 therapy; and Madrigal Pharmaceuticals presented two-year Rezdiffra data showing significant improvements in liver stiffness and fibrosis biomarkers for MASH cirrhosis patients. Avant Technologies disclosed partnerships through Insulinova with SGAustria and Klothonova with Austrianova to develop cell encapsulation therapies for diabetes and anti-aging treatments, while Prime Medicine published first-in-human PM359 data for chronic granulomatous disease demonstrating safety and efficacy of its Prime Editing technology.PR NewswireThe End of Shots? 5 Biotech Stocks Rethinking DiabetesClinical trials achieving 83% insulin independence rates are driving a major shift in metabolic disease investment, with late-2025 M&A activity reaching record valuations as pharmaceutical companies pursue curative platforms over symptom-management treatments. The article profiles five biotech companies—Avant Technologies, Novo Nordisk, Eledon Pharmaceuticals, Viking Therapeutics, and Tandem Diabetes Care—that are developing various approaches to diabetes treatment and obesity management, ranging from cell encapsulation therapies to GLP-1 receptor agonists. Analysts project the regenerative medicine market will grow from $37.98 billion in 2025 to $88.85 billion by 2030, supported by over 350 FDA expedited review designations in diabetes and metabolic diseases over the past three years.PR NewswireAvant Technologies Highlights the Critical Role of Cell Encapsulation Technology in Revolutionizing Diabetes TreatmentAvant Technologies and SGAustria Pte. Ltd. formed a joint venture and license agreement to develop cell-based therapies for diabetes using encapsulation technology. The partnership will establish Insulinova, Inc., a U.S.-based entity responsible for conducting clinical trials on genetically modified cells protected by SGAustria's Cell-in-a-Box® system.NewswireAvant Technologies Highlights the Critical Role of Cell Encapsulation Technology in Revolutionizing Diabetes TreatmentAvant Technologies and SGAustria Pte. Ltd. have formed a joint venture called Insulinova, Inc. to develop and conduct clinical trials for a cell-based diabetes treatment using SGAustria's Cell-in-a-Box® encapsulation technology. The technology protects genetically modified insulin-producing cells from immune rejection without requiring immunosuppression, potentially offering a functional cure for type 1 diabetes and reducing dependency on external insulin for type 2 patients. The partnership addresses a significant unmet need, with the International Diabetes Federation projecting 853 million people will live with diabetes globally by 2050.GlobeNewswireTHE VISIBILITY INDEX: 5 Companies Solving the Invisible CrisisThis market intelligence brief profiles five companies positioned as solutions to detection and visibility challenges across healthcare and resource sectors: Ventripoint Diagnostics, Avant Technologies, Oncolytics Biotech, GT Biopharma, and GoldHaven Resources. Ventripoint announced a strategic partnership with the Nisga'a Valley Health Authority to deploy AI-powered cardiac diagnostics in remote British Columbia communities, while Avant Technologies formed a joint venture (Insulinova) for regenerative diabetes treatment and licensed Klotho-producing cell technology for longevity applications. Oncolytics Biotech secured FDA alignment on a pivotal Phase 3 trial for pelareorep in pancreatic cancer, GT Biopharma advanced to a higher dose cohort in its Phase 1 trial for acute myeloid leukemia, and GoldHaven Resources completed its first drill hole at the Copeçal Project in Brazil's Juruena Province. The article frames these developments as infrastructure for solving "invisibility" across medicine and resource exploration, though it functions as a paid promotional advertisement for small-cap companies.NewswireAvant Technologies and Austrianova Advancing α-Klotho Cell Therapy as Mayo Clinic Study Links Low α-Klotho Levels to Poor Cardiovascular SurvivalAvant Technologies and Austrianova announced that a Mayo Clinic study published in the Journal of the American Heart Association demonstrated a strong association between declining α-Klotho levels and arterial stiffness, vascular calcification, and reduced patient survival in 148 patients. Klothonova, their 50/50 joint venture, is developing a cell-based therapy using Austrianova's Cell-in-a-Box® technology to sustainably restore circulating α-Klotho levels in patients. The study's authors concluded that further research is needed to identify targeted treatments that could prevent or reverse vascular aging processes.MarketScreenerBeyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat ConditionsThis promotional article covers the precision medicine and gene therapy sector, highlighting five biotech companies—Avant Technologies, Beam Therapeutics, CRISPR Therapeutics, Rocket Pharmaceuticals, and Schrödinger—as positioned players in a market projected to grow from $119 billion in 2025 to $471 billion by 2034. Avant Technologies announced clinical validation for its Klothonova joint venture's cell-based alpha-Klotho therapy following a Mayo Clinic study, while other covered companies reported clinical trial progress, FDA regulatory milestones, and Q3 2025 financial results. The article is a paid advertisement for Avant Technologies, with Market IQ Media Group disclosing it holds shares in the company and received compensation for coverage.Fox5sandiegoTHE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below RealityThe article discusses several companies, including Oncolytics Biotech, Avant Technologies, VisionWave Holdings, GoldHaven Resources, and VentriPoint Diagnostics, highlighting their recent developments and strategic initiatives. It emphasizes the undervaluation of these companies based on upcoming catalysts, technological innovations, and exploration results. The broader context involves market anomalies and undervaluation opportunities in various sectors such as biotech, defense, AI, and resource exploration.